论文部分内容阅读
目的 旨在探讨依膦联用钙剂及活性维生素D治疗原发性骨质疏松症 (POP)的疗效。 方法 将3 2例老年男性POP患者分成A(单用依膦 )、B(间歇期连用钙剂及活性维生素D) 2组 ,连服 2疗程 ,分别测定治疗前后腰椎骨密度 (BMD)、血清抗酒石酸酸性磷酸酶 (sTr ACP)、尿吡啶酚 (PYD)及脱氧吡啶酚 (DYD)、血清骨钙素(BGP) ,比较治疗前后各项指标变化、疼痛缓解率及骨折发生情况。 结果 3 2例POP患者服用依膦后能够明显缓解腰背痛及改善髋、膝关节痛 ,其缓解率分别为 85 2 %、82 6% ,无 1例发生骨折。A、B 2组对疼痛缓解率无差异。A组治疗前后BMD、BGP升高明显 (P <0 0 1,P <0 0 5 )。sTr ACP、PYD、DYD明显下降 (P <0 0 0 5 ) ,而B组变化更显著 (P <0 0 0 1)。 结论 依膦对POP患者具有较强抑制骨吸收 ,降低骨丢失率 ,提高骨密度及转换率 ,而间歇期连用钙剂及活性维生素D可增强依膦抗骨质疏松疗效
The purpose of this study was to investigate the therapeutic effect of etoposide combined with calcium and active vitamin D in the treatment of primary osteoporosis (POP). Methods A total of 32 elderly men with POP were divided into two groups: A (single use of phosphine) and B (intermittent calcium plus active vitamin D) for 2 courses. The BMD, STr ACP, PYD, DYD and BGP, and compared the changes before and after treatment, the pain relief rate and the incidence of fractures. Results In 32 cases of POP patients taking phosphine, they were able to relieve low back pain and improve hip and knee joint pain. The response rate was 85 2% and 82 6%, respectively. None of them had fractures. A, B 2 group pain relief rate no difference. BMD and BGP increased significantly in group A before and after treatment (P <0.01, P <0.05). sTr ACP, PYD, DYD decreased significantly (P <0 0 05), while changes in group B more significant (P 0 001). Conclusions Epinephrine can strongly inhibit bone resorption, decrease bone loss and increase BMD and turnover rate in patients with POP, while intermittent use of calcium and vitamin D may enhance the efficacy of EPO on osteoporosis